The synergistic effects of the drug combinations further support the targeting of Btk or NF-κB as a promising strategy to enhance the therapeutic efficacy of drugs for EBV-positive DLBCL with high levels of circulating CCL3 or CCL4. Here, BTK is linked to diffuse large B-cell lymphoma.